NYLIM
STRO icon

New York Life Investment Management’s Sutro Biopharma STRO Stock Holding History

New York Life Investment Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-6,901
Closed -$558K – 1382
2022
Q4 		$558K Buy
6,901
+778
+13% +$54.1K 0.01% 836
2022
Q3 		$340K Buy
6,123
+450
+8% +$26.6K ﹤0.01% 1048
2022
Q2 		$296K Buy
+5,673
New +$317K ﹤0.01% 1156

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

New York Life Investment Management's STRO Position: Q1 2023 in Review

New York Life Investment Management sold out of Sutro Biopharma (STRO) in Q1 2023, closing a stake of 6,901 shares — an estimated $558K sold.

New York Life Investment Management first reported a position in STRO in Q2 2022 and held it in 3 quarters. The position peaked at $558K in Q4 2022. 115 funds tracked by Wall St. Rank hold STRO as of Q1 2023.

  • New York Life Investment Management reported no remaining Sutro Biopharma position as of Q1 2023 after selling out during the quarter.
  • New York Life Investment Management sold 6,901 Sutro Biopharma shares in Q1 2023, an estimated $558K.
  • New York Life Investment Management first reported a position in Sutro Biopharma in Q2 2022 and held it in 3 quarters.
  • New York Life Investment Management's Sutro Biopharma position peaked at $558K in Q4 2022.
  • 115 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2023.

Based on New York Life Investment Management's 13F filing for Q1 2023, filed 8 May 2023.